UBS/CALL/ASTRAZENECA ADR/80/0.1/17.01.25

UBS/CALL/ASTRAZENECA ADR/80/0.1/17.01.25 Share Price

DE000UM5ESJ3

Market Closed - Boerse Frankfurt Warrants 11:09:51 01/07/2024 pm IST
0.52 ^EUR	-5.45%

Current month

-5.45%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart UBS/CALL/ASTRAZENECA ADR/80/0.1/17.01.25

Latest news about ASTRAZENECA PLC

Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology	30/11	PR
New analysis of Phase II data at AACR assesses ImaginAb's investigational CD8 ImmunoPET technology's ability to predict response in immunotherapy	14/23/14	PR
Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research	27/22/27	PR
Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer	14/22/14	PR

More news

Quotes 5-day view

Date	Price	Change
01/24/01	0.52	-5.45%
28/24/28	0.55	0.00%
27/24/27	0.55	-9.84%
26/24/26	0.61	-3.17%
25/24/25	0.63	-1.56%

Real-time Boerse Frankfurt Warrants

Last update July 01, 2024 at 11:09 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	UBS
WKN	UM5ESJ
ISIN	DE000UM5ESJ3
Date issued	14/05/2024
Strike	80 $
Maturity	17/01/2025 (200 Days)
Parity	10 : 1
Emission price	0.49 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.69 €
Lowest since issue	0.52 €
Delta	0.52x
Omega	6.823
Premium	10.25x
Gearing	13.19x
Moneyness	0.9740
Difference Strike	2.06 $
Difference Strike %	+2.58%
Spread	0.06 €
Spread %	10.34%
Theoretical value	0.5500
Implied Volatility	27.24 %
Total Loss Probability	55.57 %
Intrinsic value	0.000000
Present value	0.5500
Break even	85.91 €
Theta	-0.01x
Vega	0.02x
Rho	0.02x

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company